<![CDATA[FUJIREBIO 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=44689>Wed, 29 Apr 2026 10:16:35 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay]]>https://www.newswire.co.kr/newsRead.php?no=1030461Tue, 17 Mar 2026 16:20:00 +0900<![CDATA[후지레비오, 완전 자동화된 루미펄스 G NfL 혈액 검사 CE 마킹 획득 발표]]>https://www.newswire.co.kr/newsRead.php?no=1030462Tue, 17 Mar 2026 16:20:00 +0900<![CDATA[Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing]]>https://www.newswire.co.kr/newsRead.php?no=1028360Fri, 06 Feb 2026 15:50:00 +0900<![CDATA[후지레비오-시스멕스, 치매 검사 판매 협력 시작]]>https://www.newswire.co.kr/newsRead.php?no=1028361Fri, 06 Feb 2026 15:50:00 +0900<![CDATA[Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only]]>https://www.newswire.co.kr/newsRead.php?no=1027795Thu, 29 Jan 2026 10:40:00 +0900<![CDATA[후지레비오, 연구 전용 완전 자동화 ‘루미펄스 G pTau 217 CSF’ 분석법 출시로 신경 검사 포트폴리오 확장]]>https://www.newswire.co.kr/newsRead.php?no=1027797Thu, 29 Jan 2026 10:40:00 +0900<![CDATA[Notice Concerning Change of Representative Executive Officer]]>https://www.newswire.co.kr/newsRead.php?no=1027020Thu, 15 Jan 2026 15:10:00 +0900<![CDATA[H.U. 그룹 홀딩스, 대표집행임원 변경 발표]]>https://www.newswire.co.kr/newsRead.php?no=1027021Thu, 15 Jan 2026 15:10:00 +0900<![CDATA[Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries]]>https://www.newswire.co.kr/newsRead.php?no=1013687Tue, 24 Jun 2025 16:20:00 +0900<![CDATA[후지레비오, 플라즈마 서비스 그룹 인수로 IVD 및 생명과학 산업에 필수적인 고품질 생물학적 원료 공급업체로서의 입지 강화]]>https://www.newswire.co.kr/newsRead.php?no=1013688Tue, 24 Jun 2025 16:20:00 +0900<![CDATA[Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research]]>https://www.newswire.co.kr/newsRead.php?no=1012751Tue, 10 Jun 2025 09:50:00 +0900<![CDATA[후지레비오, 감염병 연구 발전을 위해 스탠퍼드 메디신과 전략적 협력 발표]]>https://www.newswire.co.kr/newsRead.php?no=1012752Tue, 10 Jun 2025 09:50:00 +0900<![CDATA[Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only]]>https://www.newswire.co.kr/newsRead.php?no=1012596Thu, 05 Jun 2025 17:10:00 +0900<![CDATA[후지레비오, 연구 전용의 완전 자동화된 루미펄스 G sTREM2 분석 출시로 신경 검사 포트폴리오 확장]]>https://www.newswire.co.kr/newsRead.php?no=1012597Thu, 05 Jun 2025 17:10:00 +0900<![CDATA[Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease]]>https://www.newswire.co.kr/newsRead.php?no=1011363Sun, 18 May 2025 15:15:00 +0900<![CDATA[후지레비오, 알츠하이머병 관련 아밀로이드 병리 환자 식별 보조 도구로 루미펄스(Lumipulse® G pTau 217/ β-아밀로이드 1-42 혈장비 체외 진단 검사에 대한 마케팅 허가 획득]]>https://www.newswire.co.kr/newsRead.php?no=1011364Sun, 18 May 2025 15:15:00 +0900<![CDATA[Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis]]>https://www.newswire.co.kr/newsRead.php?no=1010046Thu, 24 Apr 2025 16:10:00 +0900<![CDATA[플럭서스, 결핵 초민감성 소변 검사 개발을 위한 GHIT 기금의 연구 보조금 수혜]]>https://www.newswire.co.kr/newsRead.php?no=1010047Thu, 24 Apr 2025 16:10:00 +0900<![CDATA[Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy]]>https://www.newswire.co.kr/newsRead.php?no=1007814Wed, 19 Mar 2025 17:20:00 +0900<![CDATA[후지레비오 유럽, 개인 맞춤형 HCV 치료의 효율적 보조 솔루션인 INNO-LiPA® HCV 2.0 제노타이핑 어세이 출시]]>https://www.newswire.co.kr/newsRead.php?no=1007815Wed, 19 Mar 2025 17:20:00 +0900<![CDATA[후지레비오-에자이, 신경퇴행성 질환 분야에서 혈액 기반 바이오마커의 공동 연구 및 사회적 구현을 위한 양해각서 체결]]>https://www.newswire.co.kr/newsRead.php?no=1003473Tue, 24 Dec 2024 09:46:59 +0900<![CDATA[Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases]]>https://www.newswire.co.kr/newsRead.php?no=1003469Tue, 24 Dec 2024 09:46:17 +0900<![CDATA[ADx 뉴로사이언스와 알라마르 바이오사이언스, 파트너십 통해 맞춤형 혈액 기반 바이오마커 분석 솔루션 제공으로 바이오제약 임상 개발 가속화]]>https://www.newswire.co.kr/newsRead.php?no=999556Tue, 29 Oct 2024 14:30:00 +0900<![CDATA[ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development]]>https://www.newswire.co.kr/newsRead.php?no=999558Tue, 29 Oct 2024 14:30:00 +0900<![CDATA[Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease]]>https://www.newswire.co.kr/newsRead.php?no=997497Thu, 26 Sep 2024 10:50:00 +0900